Seenthil Chooranam for Type II Diabetes Mellitus

Phase II non randomized open clinical evaluation of Siddha medicine Seenthil Chooranam for the management of Madhumegam (Type II Diabetes Mellitus) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056858

Enrollment

Registered

2023-08-24

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: SEENTHIL CHOORANAM: This siddha drug will be given as 1gram, BD dose with Ghee, for 90 days, for the management of Type 2 Diabetes Mellitus. Control Intervention1: Not Applicable: Not A

Eligibility

Inclusion criteria

Inclusion criteria: 1 Sex: All Gender 2 Polyuria 3 Polyphagia 4 Polydipsia 5 Nocturia 6 HbA1C - 6.5% to 9%

Exclusion criteria

Exclusion criteria: 1 Pregnant women 2 Lactating mothers 3 Insulin dependent Diabetes mellitus 4 Cardiovascular disease 5 Diabetic nephropathy 6 Diabetic retinopathy • Recently diagnosed patient with tuberculosis • HbA1c > 9% The above criteria will be excluded clinically or based on the available medical reports.

Design outcomes

Primary

Measure	Time frame
Reduction in HbA1C level (at least 20%)Timepoint: 90 Days	—

Secondary

Measure	Time frame
Reduction in clinical symptoms like Polyuria,Polydipsia,Polyphagia & Fatigue.Timepoint: 90 Days	—

Countries

India

Contacts

Public ContactRohini alias Elavarasi J

Government Siddha Medical College,Chennai

rangasamymenaka75@gmail.com9444669661

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026